THE SMITH-FREE GROUP, LLC for TEVA PHARMACEUTICALS USA, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 2853 BLOCKING Act of 2021 (All sections of full text). P.L. 117-169, Inflation Reduction Act of 2022 (All sections of full text). S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text). Discussions regarding S. 3799, PREVENT Pandemics Act of 2022. Discussions regarding the reauthorization of Generic Drug User Fee Amendments included in P.L.117-95, Extension of Continuing Appropriations Act. Discussions regarding the approval of generic drugs. Discussions regarding improved education about digital health care. Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes. Monitored Medicare and prescription drug changes. Monitored discussions related to mental health legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK S DEUSER | — |
| MICHAEL A. GAFFIN | — |
| ROBERT HICKMOTT | — |
| TREVOR W. KOLEGO | — |
Copyright/Patent/Trademark CPT
Monitored HR 7377, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored S. 1463, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored discussions related to FDA 'skinny labelling' issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A. GAFFIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.